A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.

The purpose of this study was to evaluate the safety and efficacy of preoperative capecitabine and radiation therapy (RT) in patients with locally advanced rectal cancer (LARC).
Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50.4 Gy of RT in 28 1.8-Gy fractions. Patients with metastatic disease were eligible provided that operative intervention on primary site was anticipated. Surgery resection occurred 4 to 6 weeks after completion of preoperative therapy.
Thirty eligible patients were enrolled at two institutions. Median age and performance status were 62 years and 90%, respectively. Twenty-eight patients (93%) completed combined modality therapy and 27 underwent resection, including 17 abdominal-perineal and 9 low anterior resections. Three of 27 (11%) had pathologic complete response (pCR) with an additional 7 (26%) having minimal residual disease. Two patients who were felt to require abdominal perineal resection prior to combined modality therapy (CMT) were able to have sphincter-sparing surgery. No patients had progression during CMT which precluded surgical resection. Treatment was well tolerated with >or=grade 3 toxicities limited to diarrhea (5 patients), hand-foot syndrome (1 patient), dermatitis (1 patient). Twenty-four patients are living, 18 with no evidence of disease.
The combination of preoperative capecitabine and RT in patients with LARC has significant antitumor activity, efficacy, and a low toxicity profile.
AuthorsSameer P Desai, Basil F El-Rayes, Edgar Ben-Josef, Joel K Greenson, James A Knol, Emina H Huang, Kent A Griffith, Philip A Philip, Cornelius J McGinn, Mark M Zalupski
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 30 Issue 4 Pg. 340-5 (Aug 2007) ISSN: 1537-453X [Electronic] United States
PMID17762432 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Capecitabine
  • Fluorouracil
  • Adenocarcinoma (drug therapy, radiotherapy, secondary)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic (therapeutic use)
  • Capecitabine
  • Combined Modality Therapy
  • Deoxycytidine (analogs & derivatives, therapeutic use)
  • Disease-Free Survival
  • Female
  • Fluorouracil (analogs & derivatives, therapeutic use)
  • Humans
  • Liver Neoplasms (secondary)
  • Lung Neoplasms (secondary)
  • Male
  • Middle Aged
  • Preoperative Care
  • Rectal Neoplasms (drug therapy, pathology, radiotherapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: